Literature DB >> 16079118

e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.

Giovanni Roti, Roberta La Starza, Paolo Gorello, Enrico Gottardi, Barbara Crescenzi, Massimo F Martelli, Cristina Mecucci.   

Abstract

This is the first report of e6a2 and e1a2 BCR/ABL1 positive chronic myeloid leukemia (CML) with cryptic deletions of the 5'ABL1 and 3'BCR in separate clones which differ in genomic regions of the deleted der(9). Both deletions were detected throughout monitoring. Imatinib mesylate stabilized this CML with rare genetic aberrations for a relatively long time.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16079118

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  3 in total

1.  BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.

Authors:  Antonella Zagaria; Luisa Anelli; Nicoletta Coccaro; Giuseppina Tota; Paola Casieri; Angelo Cellamare; Luciana Impera; Claudia Brunetti; Angela Minervini; Crescenzio Francesco Minervini; Mario Delia; Cosimo Cumbo; Paola Orsini; Giorgina Specchia; Francesco Albano
Journal:  Virchows Arch       Date:  2015-07-07       Impact factor: 4.064

2.  A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.

Authors:  Jinjuan Yao; Dan Douer; Lu Wang; Maria E Arcila; Khedoudja Nafa; April Chiu
Journal:  Leuk Res Rep       Date:  2017-01-31

3.  Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Authors:  Marte Karen Brattås; Kyrre Lilleeng; Randi Hovland; Ingvild Jenssen Lægreid; Marta Vorland; Friedemann Leh; Øystein Bruserud; Bjørn Tore Gjertsen; Håkon Reikvam
Journal:  Biomark Res       Date:  2018-11-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.